skip to Main Content

Cornnavirus Variants List

The heavily glycosylated spike (S) protein on its surface give Coronavirus a crown-like appearance. These surface proteins recognize the ACE2 receptors displayed on host cells and facilitate viral entry. As a key determinant of host and cell tropism, antigenicity and immunogenicity, interspecies transmission and pathogenesis1 the spike protein is an attractive target for antiviral inhibitors and vaccines 2,3,4. Changes to the amino acid of the spike protein lead to the emergence of new coronavirus variants and will continue to do so.

Amino acid changes that occur during the virus life cycle have can increase transmissibility or virulence of the virus. The table below lists the variants on the  World Health Organization  (WHO) and the CDC watchlist.  The ongoing evolution of SARS-CoV-2 will require continuous research and development to create a therapeutic pipeline to effectively protect against COVID-19. At IBT BioServices we offer a neutralization assay for evaluating antiviral efficacy using recombinant viruses pseudotyped to express the Spike from SARS-CoV2 variants of concern listed below.

Common Name (Origin)
Lineage
Spike Amino Acid Mutations
Wild-type
(Wuhan)
Parental Strain
--
Alpha
(United Kingdom)
B.1.1.7/501Y.V1
del69–70 HV, del144 Y, N501Y, A570D, D614G, P681H, T761I, S982A, D1118H
Beta
(South Africa)
B.1.351
K417N, E484K, N501Y, D614G, A701V
Gamma
(Brazil)
P.1
L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I
Delta
(India)
B.1.617
L452R, E484Q
Epsilon
(California, USA)
B.1.427
B.1.429
L452R, D614G
SS13I, W152C, L452R, D614G
D614G (--)
--
D614G
Lambda
B.37
G75V(77) T76I(77) R246del(245) S247del(245) Y248del(250) L249del(250) T250del P251del(250) G252del(250) D253N(250) L452Q F490S T547I D614G T859N
Mu
B.621
D614G, D950N, E484K, ins145N, N501Y, P681H, R346K, T95I, Y144T, Y145S
Omicron
B.1.1529
A67V H69del V70del(69) T95I G142D V143del Y144del(143) Y145del(143) N211del L212I ins214EPE G339D S371L S373P S375F K417N N440K G446S S477N T478K E484A Q493R G496S Q498R N501Y Y505H T547K D614G H655Y N679K(674) P681H(674) N764K D796Y N856K Q954H N969K L981F
Back To Top
Search
Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.